Search research articles
Contact Us
Filters
Showing results (91-100 of 111) with videos related to
Page
of 12
Sort By:
Cell Reports
|
February 6, 2022
A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
Guillaume Beaudoin-Bussières, Yaozong Chen, Irfan Ullah, et al.
Journal of Virology
|
July 7, 2021
Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells
Sai Priya Anand, Shilei Ding, William D Tolbert, et al.
Cell Host & Microbe
|
April 12, 2019
An Asymmetric Opening of HIV-1 Envelope Mediates Antibody-Dependent Cellular Cytotoxicity
Nirmin Alsahafi, Nordine Bakouche, Mohsen Kazemi, et al.
Nucleic Acids Research
|
September 13, 2011
Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase
Tanyaradzwa P Ndongwe, Adeyemi O Adedeji, Eleftherios Michailidis, et al.
Biorxiv : the Preprint Server for Biology
|
August 10, 2021
Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern
Wenwei Li, Yaozong Chen, Jérémie Prévost, et al.
Journal of Virology
|
October 13, 2025
Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants
Shilei Ding, Derek Yang, Irfan Ullah, et al.
Cell Reports
|
December 31, 2021
Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern
Wenwei Li, Yaozong Chen, Jérémie Prévost, et al.
Frontiers in Immunology
|
May 30, 2019
Immune Correlates of Disease Progression in Linked HIV-1 Infection
Michael Tuen, Jude S Bimela, Andrew N Banin, et al.
Cell Reports
|
February 26, 2022
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses
Debashree Chatterjee, Alexandra Tauzin, Lorie Marchitto, et al.
Cell Reports
|
October 16, 2022
A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
Alexandra Tauzin, Shang Yu Gong, Debashree Chatterjee, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 111) with videos related to
Sort By:
Page
of 12
Cell Reports
|
February 6, 2022
A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
Guillaume Beaudoin-Bussières, Yaozong Chen, Irfan Ullah, et al.
Journal of Virology
|
July 7, 2021
Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells
Sai Priya Anand, Shilei Ding, William D Tolbert, et al.
Cell Host & Microbe
|
April 12, 2019
An Asymmetric Opening of HIV-1 Envelope Mediates Antibody-Dependent Cellular Cytotoxicity
Nirmin Alsahafi, Nordine Bakouche, Mohsen Kazemi, et al.
Nucleic Acids Research
|
September 13, 2011
Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase
Tanyaradzwa P Ndongwe, Adeyemi O Adedeji, Eleftherios Michailidis, et al.
Biorxiv : the Preprint Server for Biology
|
August 10, 2021
Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern
Wenwei Li, Yaozong Chen, Jérémie Prévost, et al.
Journal of Virology
|
October 13, 2025
Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants
Shilei Ding, Derek Yang, Irfan Ullah, et al.
Cell Reports
|
December 31, 2021
Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern
Wenwei Li, Yaozong Chen, Jérémie Prévost, et al.
Frontiers in Immunology
|
May 30, 2019
Immune Correlates of Disease Progression in Linked HIV-1 Infection
Michael Tuen, Jude S Bimela, Andrew N Banin, et al.
Cell Reports
|
February 26, 2022
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses
Debashree Chatterjee, Alexandra Tauzin, Lorie Marchitto, et al.
Cell Reports
|
October 16, 2022
A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
Alexandra Tauzin, Shang Yu Gong, Debashree Chatterjee, et al.
Page
of 12